Drug Trial Radar · NCT06817889
Remdesivir for the Treatment of Upper Respiratory Tract Infection Due to RSV in Immunocompromised Individuals
Last checked: Nov 20, 2026Latest source record: Oct 1, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
60
Planned (sponsor's estimate)
Start
Dec 23, 2025
Primary completion
Nov 30, 2027
Study completion Nov 30, 2027
Sponsor
- Lead sponsor
- Fred Hutchinson Cancer CenterAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- Collaborators
- Gilead Sciences
- First posted
- Feb 10, 2025
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This phase II trial tests how well remdesivir works for treatment of respiratory syncytial virus (RSV) infection of the upper respiratory tract in patients receiving cellular or bispecific antibody therapy. Cellular or bispecific antibody therapies cause suppression of the immune system, making infections more frequent and reducing the body's ability to fight the infections. RSV infections are one of the most common respiratory infections in immunocompromised individuals and can cause significant pneumonia and even death. Remdesivir is in a class of medications called antivirals. It works by stopping viruses from spreading in the body.
Conditions
- Hematopoietic and Lymphatic System Neoplasm
- Autoimmune Disease
- Respiratory Syncytial Virus Infection
Interventions
RemdesivirDrug
Given IV
Survey AdministrationOther
Ancillary studies
Biospecimen CollectionProcedure
Undergo blood sample collection
Nasal SwabProcedure
Undergo nasal swabs
Primary outcomes
What the sponsor says the trial is designed to measure.
- Proportion of participants requiring ≥ 2 liters/minute of oxygen for ≥ 24 consecutive hoursTime frame: Up to day 29
Locations
3 sites in 1 country. Site status is shown where the registry gives one.
City of Hope Comprehensive Cancer Center
Duarte, California · Recruiting
MD Anderson Cancer Center
Houston, Texas · Recruiting
Fred Hutch/University of Washington Cancer Consortium
Seattle, Washington · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.